COVID-19灭活疫苗与组粒感染后恢复男性精液质量的关系：一项回顾性队列研究

IF 3.9 3区医学 Q2 IMMUNOLOGY

Expert Review of Clinical Immunology Pub Date : 2025-05-15 DOI:10.1080/1744666X.2025.2507329

Yunlong Li, Yinxia Su, Yangchang Zhang, Zihao Guo, Zhaoyun Chen, Hui Li, Chunyang Zhang, Qiaoge Chi, Yang Ge, Mohammad Javanbakht, Salihu S Musa, Shengzhi Sun, Naijun Tang, Kai Wang, Kailu Wang, Shi Zhao

{"title":"COVID-19灭活疫苗与组粒感染后恢复男性精液质量的关系：一项回顾性队列研究","authors":"Yunlong Li, Yinxia Su, Yangchang Zhang, Zihao Guo, Zhaoyun Chen, Hui Li, Chunyang Zhang, Qiaoge Chi, Yang Ge, Mohammad Javanbakht, Salihu S Musa, Shengzhi Sun, Naijun Tang, Kai Wang, Kailu Wang, Shi Zhao","doi":"10.1080/1744666X.2025.2507329","DOIUrl":null,"url":null,"abstract":"Background: The protective effects of inactivated COVID-19 vaccines against SARS-CoV-2-associated semen impairment remain underexplored. We investigated associations between BBIBP-CorV vaccination and the semen quality in males recovering from SARS-CoV-2 infection.Research design and methods: This single-center retrospective cohort study included 1,496 males recovering from SARS-CoV-2 infection at a tertiary hospital in Urumqi, China (February-May 2023). Participants were categorized into long-term and short-term effects groups based on the interval between semen collection and their most recent SARS-CoV-2 infection. The study assessed the association between the different doses of BBIBP-CorV vaccination and semen quality in both groups.Results: A total of 1496 participants were recruited for the short-term (n = 307) and long-term effect groups (n = 1189). Participants had a median age of 32 (IQR: 30, 35). Compared to unvaccinated controls, 2-dose and 3-dose recipients showed reduced short-term semen quality impairment risks, with adjusted RR of 0.945 (95% CI 0.918, 0.973) and 0.965 (95% CI 0.937, 0.993), respectively. No significant results were found for long-term effect groups.Conclusion: Inactivated COVID-19 vaccination may protect against semen quality impairment among males recovering from SARS-CoV-2 Omicron infection within 90 days, especially in terms of semen volume and sperm progressive motility.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between inactivated COVID-19 vaccine and semen quality among males recovered from omicron infection: a retrospective cohort study.\",\"authors\":\"Yunlong Li, Yinxia Su, Yangchang Zhang, Zihao Guo, Zhaoyun Chen, Hui Li, Chunyang Zhang, Qiaoge Chi, Yang Ge, Mohammad Javanbakht, Salihu S Musa, Shengzhi Sun, Naijun Tang, Kai Wang, Kailu Wang, Shi Zhao\",\"doi\":\"10.1080/1744666X.2025.2507329\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The protective effects of inactivated COVID-19 vaccines against SARS-CoV-2-associated semen impairment remain underexplored. We investigated associations between BBIBP-CorV vaccination and the semen quality in males recovering from SARS-CoV-2 infection.Research design and methods: This single-center retrospective cohort study included 1,496 males recovering from SARS-CoV-2 infection at a tertiary hospital in Urumqi, China (February-May 2023). Participants were categorized into long-term and short-term effects groups based on the interval between semen collection and their most recent SARS-CoV-2 infection. The study assessed the association between the different doses of BBIBP-CorV vaccination and semen quality in both groups.Results: A total of 1496 participants were recruited for the short-term (n = 307) and long-term effect groups (n = 1189). Participants had a median age of 32 (IQR: 30, 35). Compared to unvaccinated controls, 2-dose and 3-dose recipients showed reduced short-term semen quality impairment risks, with adjusted RR of 0.945 (95% CI 0.918, 0.973) and 0.965 (95% CI 0.937, 0.993), respectively. No significant results were found for long-term effect groups.Conclusion: Inactivated COVID-19 vaccination may protect against semen quality impairment among males recovering from SARS-CoV-2 Omicron infection within 90 days, especially in terms of semen volume and sperm progressive motility.\",\"PeriodicalId\":12175,\"journal\":{\"name\":\"Expert Review of Clinical Immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1744666X.2025.2507329\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2025.2507329","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：COVID-19灭活疫苗对sars - cov -2相关精液损伤的保护作用尚不清楚。我们研究了BBIBP-CorV疫苗接种与SARS-CoV-2感染恢复期男性精液质量之间的关系。研究设计与方法：本研究为单中心回顾性队列研究，纳入2023年2月- 5月在乌鲁木齐市某三级医院SARS-CoV-2感染恢复期男性1496例。根据收集精液和最近一次感染SARS-CoV-2之间的间隔，参与者被分为长期和短期效果组。该研究评估了两组不同剂量的BBIBP-CorV疫苗接种与精液质量之间的关系。结果：短期组（n = 307）和长期组（n = 1189）共招募了1496名参与者。参与者的中位年龄为32岁（IQR: 30,35）。与未接种疫苗的对照组相比，2剂和3剂接种者的短期精液质量受损风险降低，调整后的RR分别为0.945 （95% CI 0.918, 0.973）和0.965 （95% CI 0.937, 0.993）。长期效应组没有发现显著的结果。结论：COVID-19灭活疫苗可预防SARS-CoV-2 Omicron感染后90天内恢复期男性精液质量受损，尤其是在精液量和精子进进活力方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association between inactivated COVID-19 vaccine and semen quality among males recovered from omicron infection: a retrospective cohort study.

Background: The protective effects of inactivated COVID-19 vaccines against SARS-CoV-2-associated semen impairment remain underexplored. We investigated associations between BBIBP-CorV vaccination and the semen quality in males recovering from SARS-CoV-2 infection.

Research design and methods: This single-center retrospective cohort study included 1,496 males recovering from SARS-CoV-2 infection at a tertiary hospital in Urumqi, China (February-May 2023). Participants were categorized into long-term and short-term effects groups based on the interval between semen collection and their most recent SARS-CoV-2 infection. The study assessed the association between the different doses of BBIBP-CorV vaccination and semen quality in both groups.

Results: A total of 1496 participants were recruited for the short-term (n = 307) and long-term effect groups (n = 1189). Participants had a median age of 32 (IQR: 30, 35). Compared to unvaccinated controls, 2-dose and 3-dose recipients showed reduced short-term semen quality impairment risks, with adjusted RR of 0.945 (95% CI 0.918, 0.973) and 0.965 (95% CI 0.937, 0.993), respectively. No significant results were found for long-term effect groups.

Conclusion: Inactivated COVID-19 vaccination may protect against semen quality impairment among males recovering from SARS-CoV-2 Omicron infection within 90 days, especially in terms of semen volume and sperm progressive motility.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Clinical Immunology IMMUNOLOGY-

CiteScore

7.60

自引率

2.30%

发文量

221

审稿时长

6-12 weeks

期刊介绍： Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.